David Shaw’s Novo Nordisk NVO Stock Holding History

David Shaw’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244M	Sell	5,087,000 -755,000	-13%	-$32.4M	0.12%	171
2026 Q1	$215M	Buy	5,842,000 +170,900	+3%	+$8.1M	0.13%	177
2025 Q4	$289M	Buy	5,671,100 +3,163,600	+126%	+$162M	0.16%	120
2025 Q3	$139M	Buy	2,507,500 +867,000	+53%	+$50.7M	0.08%	299
2025 Q2	$113M	Buy	1,640,500 +564,800	+53%	+$38.4M	0.08%	302
2025 Q1	$74.7M	Buy	1,075,700 +469,500	+77%	+$38.8M	0.07%	350
2024 Q4	$52.1M	Buy	606,200 +520,400	+607%	+$56.3M	0.04%	558
2024 Q3	$10.2M	Buy	85,800 +72,800	+560%	+$9.71M	0.01%	1416
2024 Q2	$1.86M	Hold	13,000	–	–	﹤0.01%	2717
2024 Q1	$1.67M	Sell	13,000 -77,000	-86%	-$9.17M	﹤0.01%	2761
2023 Q4	$9.31M	Buy	90,000 +13,000	+17%	+$1.29M	0.01%	1415
2023 Q3	$7M	Hold	77,000	–	–	0.01%	1542
2023 Q2	$6.23M	Buy	77,000 +59,800	+348%	+$4.89M	0.01%	1703
2023 Q1	$1.37M	Buy	+17,200	New	+$1.22M	﹤0.01%	2946

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

David Shaw's NVO Position: Q2 2026 in Review

David Shaw reduced its Novo Nordisk (NVO) stake by 66% in Q2 2026, selling an estimated $57.6M and leaving 697,567 shares worth $33.4M. The position accounts for 0.02% of the portfolio, ranked #983.

David Shaw first reported a position in NVO in Q2 2013 and has held it in 40 quarters since. The position peaked at $179M in Q1 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

David Shaw held 697,567 shares of Novo Nordisk worth $33.4M as of Q2 2026.
David Shaw sold 1,341,539 Novo Nordisk shares in Q2 2026, an estimated $57.6M.
Novo Nordisk made up 0.02% of David Shaw's portfolio in Q2 2026, its #983 holding.
David Shaw first reported a position in Novo Nordisk in Q2 2013 and has held it in 40 quarters since.
David Shaw's Novo Nordisk position peaked at $179M in Q1 2025.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.